CN109776676A - 针对艰难梭菌的抗体 - Google Patents

针对艰难梭菌的抗体 Download PDF

Info

Publication number
CN109776676A
CN109776676A CN201811406032.6A CN201811406032A CN109776676A CN 109776676 A CN109776676 A CN 109776676A CN 201811406032 A CN201811406032 A CN 201811406032A CN 109776676 A CN109776676 A CN 109776676A
Authority
CN
China
Prior art keywords
antibody
ser
seq
antigen
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811406032.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·卡桑
D·约翰斯通
L·萨沃德
J·A·乔治
J·贝里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CNJ Holdings Inc
Original Assignee
CNJ Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CNJ Holdings Inc filed Critical CNJ Holdings Inc
Publication of CN109776676A publication Critical patent/CN109776676A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201811406032.6A 2012-11-28 2013-11-29 针对艰难梭菌的抗体 Pending CN109776676A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730790P 2012-11-28 2012-11-28
US61/730,790 2012-11-28
CN201380071593.4A CN105025926B (zh) 2012-11-28 2013-11-29 针对艰难梭菌的抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380071593.4A Division CN105025926B (zh) 2012-11-28 2013-11-29 针对艰难梭菌的抗体

Publications (1)

Publication Number Publication Date
CN109776676A true CN109776676A (zh) 2019-05-21

Family

ID=50828602

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811406032.6A Pending CN109776676A (zh) 2012-11-28 2013-11-29 针对艰难梭菌的抗体
CN201380071593.4A Expired - Fee Related CN105025926B (zh) 2012-11-28 2013-11-29 针对艰难梭菌的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380071593.4A Expired - Fee Related CN105025926B (zh) 2012-11-28 2013-11-29 针对艰难梭菌的抗体

Country Status (9)

Country Link
US (1) US10117933B2 (2)
EP (1) EP2925362A4 (2)
JP (1) JP2016501877A (2)
CN (2) CN109776676A (2)
AU (2) AU2013352034B2 (2)
CA (1) CA2892973A1 (2)
HK (1) HK1216999A1 (2)
IL (1) IL239063A0 (2)
WO (1) WO2014085749A2 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853896A (zh) * 2020-11-30 2022-08-05 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
USD952157S1 (en) 2020-06-19 2022-05-17 Qualigen Inc. Whole blood treatment cartridge
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
EP4232818A1 (en) * 2020-10-20 2023-08-30 Fzata, Inc. Neutralized antibody and method of use thereof
US20250059267A1 (en) * 2021-05-14 2025-02-20 Phenomic Ai Combination therapy for treatment of tumors comprising cancer-associated fibroblasts
CN116239683B (zh) * 2023-02-15 2024-12-27 兰州生物制品研究所有限责任公司 一种抗艰难梭菌毒素b的单克隆抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130650A2 (en) * 2010-04-15 2011-10-20 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease
CN102365097A (zh) * 2009-02-20 2012-02-29 卫生防护机构 艰难梭菌毒素的抗体

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5435945A (en) 1992-05-29 1995-07-25 Procor Sulphur Services, Inc. Method and apparatus for generating sulphur seed particles for sulphur granule production
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU2003210060B2 (en) * 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
EP2857418B1 (en) * 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007065037A2 (en) * 2005-12-02 2007-06-07 Curagen Corporation Antibodies against mmp-13 (collagenase-3) and uses thereof
CA2673725C (en) * 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
AU2009219358A1 (en) * 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
WO2011063346A1 (en) * 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US9771416B2 (en) * 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
CA2834402A1 (en) * 2010-12-29 2012-07-05 Cangene Corporation Clostridium difficile antigens
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
BR112014004162A2 (pt) * 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
BR112014006175B1 (pt) * 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
EP2921502A4 (en) * 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
US10160797B2 (en) * 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US11434264B2 (en) * 2015-02-13 2022-09-06 Quanterix Corporation Immunoassays for differential detection of clostridium difficile
US10533036B2 (en) * 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102365097A (zh) * 2009-02-20 2012-02-29 卫生防护机构 艰难梭菌毒素的抗体
WO2011130650A2 (en) * 2010-04-15 2011-10-20 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREG HUSSACK,ET AL.: "Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
刘红升等: "艰难梭菌细胞毒素Ｂ功能区的原核表达及免疫原性", 《基础医学与临床》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853896A (zh) * 2020-11-30 2022-08-05 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN114853896B (zh) * 2020-11-30 2023-05-09 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用

Also Published As

Publication number Publication date
US20150290319A1 (en) 2015-10-15
JP2016501877A (ja) 2016-01-21
WO2014085749A2 (en) 2014-06-05
EP2925362A2 (en) 2015-10-07
CA2892973A1 (en) 2014-06-05
CN105025926A (zh) 2015-11-04
HK1216999A1 (zh) 2016-12-16
IL239063A0 (en) 2015-07-30
CN105025926B (zh) 2018-12-14
US10117933B2 (en) 2018-11-06
EP2925362A4 (en) 2016-07-20
WO2014085749A3 (en) 2015-07-16
AU2013352034A1 (en) 2015-07-02
AU2013352034B2 (en) 2018-08-02
AU2018256482A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
US11512129B2 (en) TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
AU2013352034B2 (en) Antibodies against Clostridium difficile
US12116402B2 (en) Antibodies against clostridium difficile toxins and methods of using the same
JP5717300B2 (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
JP6281163B2 (ja) クロストリジウム・ディフィシレ抗体
WO2020200196A1 (zh) 抗Claudin18.2抗体及其应用
KR20150073211A (ko) 항―캄필로박터 제주니 항체 및 그의 용도
CN109689090A (zh) 抗o2抗体及其用途
EP3981787A1 (en) Anti-connective tissue growth factor antibody and application thereof
US20240101649A1 (en) ANTI-CfaE ANTIBODIES AND METHODS OF USE
CA2545714C (en) Neutralizing human antibodies to anthrax toxin generated by recall technology
CN117396502A (zh) 针对肺炎球菌抗原的人类单克隆抗体
CN101357942B (zh) 一种中和肠出血性大肠杆菌0157：H7志贺毒素Ⅱ的单克隆抗体、Fab抗体与应用
EP3180024B1 (en) Anti-ospa antibodies and methods of use
HK1199886B (en) Clostridium difficile antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190521

WD01 Invention patent application deemed withdrawn after publication